You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 31, 2024

Litigation Details for Astellas Pharma Inc. v. Sandoz Inc. (D. Del. 2020)


✉ Email this page to a colleague

« Back to Dashboard


Astellas Pharma Inc. v. Sandoz Inc. (D. Del. 2020)

Docket ⤷  Sign Up Date Filed 2020-11-24
Court District Court, D. Delaware Date Terminated 2023-06-09
Cause 35:271 Patent Infringement Assigned To Joseph F. Bataillon
Jury Demand Defendant Referred To Christopher J. Burke
Parties AUROBINDO PHARMA USA, INC.
Patents 6,346,532; 6,562,375; 7,342,117; 7,982,049; 8,772,315; 8,835,474; RE44,872
Attorneys Michael K. Nutter
Firms Heyman Enerio Gattuso & Hirzel LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Astellas Pharma Inc. v. Sandoz Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Sign Up and ⤷  Sign Up .

Details for Astellas Pharma Inc. v. Sandoz Inc. (D. Del. 2020)

Date Filed Document No. Description Snippet Link To Document
2020-11-24 1 Complaint Book listed patent for Myrbetriq® Tablets, United States Patent No. 6,346,532 (“the ’532 Patent”) against… action for patent infringement of United States Patent No. 10,842,780 (“the ’780 Patent”), arising under…7,342,117 (“the ’117 Patent”), 7,982,049 (“the ’049 Patent”), 8,835,474 (“the ’474 Patent”) and RE44,872 (“the…the then-listed patents in the Orange Book for Myrbetriq® Tablets, United States Patent Nos. 7,342,117… the ’780 Patent because, inter alia, they concluded before the issuance of the ’780 Patent. External link to document
2023-02-21 523 Redacted Document accompanying Paragraph IV certification for U.S. Patent Nos. 7,342,117; 7,982,049; …accompanying Paragraph IV certification for U.S. Patent Nos. 7,342,117, 7,982,049, 8,835,474, and RE44,872 …, journal, patent, patent publication, certified file history of a patent or patent application, or… infringement of United States Patent No. 10,842,780 (“the ’780 Patent”) based on Sandoz’s September…infringement of United States Patent No. 10,842,780 (“the ’780 Patent”) based on Sandoz’s September External link to document
2023-06-09 571 Order - Memorandum and Order having been long known, e.g., U.S. Pat. No. 6,346,532; Astellas Pharma Inc. v. Actavis Elizabeth …MEMORANDUM AND ORDER, claims 5, 20, and 25 of U.S. Patent No. 10,842,780 are invalid. All pending motions…matter is before the Court for final decision on patent-infringement charges arising under the Hatch-Waxman…the heels of a previous suit involving different patents but the same Abbreviated New Drug Applications…contrasted by its inefficacy on a full one—U.S. Patent No. 10,842,780 claims the extended-release formulation External link to document
2021-03-16 78 Counterclaim AND Answer to Complaint Book listed patent for Myrbetriq® Tablets, United States Patent No. 6,346,532 (“the ‘532 Patent”) against…“Notification of Certification for U.S. Patent Nos. 6,346,532; 6,562,375; 7,342,117; 7,982,049; 8,835,474…Letter”) to the 6,346,532, 6,562,375, 7,342,117, 7,982,049, 8,835,474, and RE44,872 patent holder and the… action for patent infringement of United States Patent No. 10,842,780 (“the ‘780 Patent”), arising under…infringement of U.S. Patent No. 10,842,780 (“the 780 Patent”) arising under the United States patent laws and Title External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.